Study #2021-1203
Phase II Study of Relatlimab and Nivolumab for checkpoint blockade in patients with melanoma brain metastases (BLUEBONNET)
MD Anderson Study Status
Enrolling
Treatment Agent
BMS-986213 (Relatlimab-Nivolumab FDC), Nivolumab, Relatlimab
Description
To learn if giving nivolumab in combination with relatlimab can help to control melanoma that has spread to the brain (melanoma with brain metastases). The safety and side effects of the study drug combination will also be studied.
Resources and Links
Phone Number: 1-877-MDA-6789
Information and next steps
Disease:
Melanoma (Skin)
Study phase:
Phase II
Physician name:
Hussein Tawbi
Department:
Melanoma Medical Oncology
For general questions about clinical trials:
1-877-632-6789
Help #EndCancer
Give Now
Your gift will help make a tremendous difference.
Donate Blood
Our patients depend on blood and platelet donations.
Shop MD Anderson
Show your support for our mission through branded merchandise.